-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Century Therapeutics, Lowers Price Target to $6

Benzinga·05/16/2025 22:33:52
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $7 to $6.